OCT devices hold promise

Article

The future of OCT seems almost limitless and for Dr Jay S. Duker, many more new innovations are expected.

The future of OCT seems almost limitless and for Dr Jay S. Duker, many more new innovations are expected.

"The OCT story is one of engineering success triumphing over darkness," said Dr Duker. In looking at the history of the technology he explained that time domain was very useful but not perfect with registration errors, skip areas, software breakdowns and, often, inadequate resolution. Spectral domain technology has been commercially available since 2006 and is faster than the previous time domain OCT.

However, in Dr Duker's opinion the innovations do not stop there. "We will see better light sources with broader bandwidths that theoretically get axial resolution down to 1 µm," he said. Not only this, but he believes there will be longer wavelengths in the future that will enable better penetration of the optic nerve and choroid for better disease insight and less scattering to improve through-cataract imaging.

Increased speed is another advancement that will happen soon. The swept source OCT is set to become commercially available shortly and will offer much faster scan speeds. Dr Duker explained that these quicker devices will also provide a higher pixel density to allow visualization of high-quality images.

"High speed over large areas will provide beautiful video images that will allow cross-sectional scans to be obtained of virtually any retinal layer from the inner retina to the capillaries to the outer retina and into the optic nerve," he added. "This technology might even supplant fluorescein angiography and even indocyanine green angiography…"

If you would like to read more about the promise OCT devices hold, Dr Duker's article can be found in the May print issue of OTEurope.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.